Price History

Hover for the daily close. The dotted line marks the period open.

Compare SPRB with… →

SPRB Key Statistics

As of Sep 4, 2026

Trading

Open: $57.37
Previous Close: $57.71
Day's Range: 56.57–58.19
52-Week Range: 7.26–240.00
Volume: 103.90K
Beta: 3.36

Valuation

Market Cap: $166.49M
P/E Ratio: unprofitable
Forward P/E: 7.09
EPS (ttm): −38.85

Financials (FY)

Revenue (FY): $0.00−100.00%
Net Income (FY): −$38.97M
Profit margin: 0.00%
Shares Outstanding: 2.87M
1-Year Return: +559.04%

Dividend and dates

Avg Volume: 73.19K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

SPRB Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+43.00%−81.65%−75.40%+167.09%−85.67%−96.31%−33.50%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	−33.50%
2025	−96.31%
2024	−85.67%
2023	+167.09%
2022	−75.40%
2021	−81.65%
2020 (partial year)	+43.00%

As of September 4, 2026.

SPRB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$38.97M	—
2024	$4.91M	−$53.04M	−1079.9%
2023	$10.09M	−$47.92M	−475.0%
2022	$0.00	−$46.18M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$36.51M	−$38.97M	—
2024	$4.91M	—	−$56.15M	−$53.04M	−1079.9%
2023	$10.09M	—	−$51.99M	−$47.92M	−475.0%
2022	$0.00	—	−$47.28M	−$46.18M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

SPRB Valuation vs Biotechnology Median

Median of 656 stocks

Metric	SPRB	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Spruce Biosciences, Inc. (SPRB) carries a market capitalisation of $166.49M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 22 employees.

The most recent close on file for SPRB is $57.93, dated September 4, 2026. That is +$0.22 (+0.38%) against the previous close. The 52-week range on file runs from $7.26 to $240.00. The latest close sits 697.93% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. Against the prior fiscal year total of $4.91M, that is a change of −100.00%. The same year closed with a net loss of $38.97M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −38.85.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 7.09.

Over the trailing twelve months the price has returned +559.04%. Across 5 years the annualized return works out at −73.51%. Beta against the wider market is reported at 3.36. Annualized volatility over the trailing 5 years is 630.49%.

Growth & Income

The record shows no dividend for SPRB.

The strongest complete calendar year on file is 2023 at +167.09%; the weakest is 2025 at −96.31%. Of the 5 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −33.50% year to date.

Peer Comparison

Spruce Biosciences, Inc. (SPRB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Spruce Biosciences, Inc.	SPRB	$166.49M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Spruce Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.

Visit website →

Spruce Biosciences, Inc. (SPRB) Stock Analysis